Monday, May 19, 2025

Certis Oncology Announces Closing of $10 Million Series C Fundraising Round

Related stories

The Hidden Risks of Data Lakes: What AI Developers Need to Know About Database Exposure

Organizations are racing to use artificial intelligence. Many are...

Proofpoint Announces Agreement to Acquire Hornetsecurity

Strategic acquisition marks significant milestone in advancing Proofpoint’s mission...

Reply Introduces AI Silicon Shoring for Software Delivery

Reply, a leading global systems integrator and technology consulting...

QAD and Boomi Partner to Revolutionize Smart Manufacturing

QAD Inc., a leader in cloud-based manufacturing and connected...
spot_imgspot_img

Certis Oncology Solutions, a precision oncology and translational science company focused on combining AI-directed drug development with advanced functional testing, announced that it raised $10 million in a Series C funding round, bringing total raised to $42 million. The company also named John R. Tozzi Chairman of its Board of Directors.

“We welcome John’s leadership and this additional investment at this critical inflection point for our company,” said Peter Elman, President and CEO of Certis. “Now serving more than 120 oncology therapeutics companies, we have established the necessary business traction to see a clear path to profitable growth. At the same time, ongoing validation studies give us great confidence that our proprietary CertisAI™ predictive oncology platform soon will be able to deliver truly personalized cancer treatment at scale.”

Also Read: Rad AI Announces Partnership with Google to Move Radiology Reporting Forward with AI

New Certis Board of Directors Chairman, John Tozzi, who also serves as the Certis Chairman of the Executive and Finance Committees, led the company’s last two internal funding rounds, as well as this most recent raise in which 94% of the company’s top 50 investors participated. “Our investors are passionate about the company’s patient-focused mission and 100% behind its three-pronged strategy for creating shareholder value: building a best-in-class bank of advanced tumor models for cancer research, developing disruptive AI-based intellectual property, and generating services revenue from very specialized contract research to help fund R&D,” he said. In 1982 Mr. Tozzi founded Cambridge Investments LLC, an investment management firm, and continues to serve as its CEO and CIO.

Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. The company’s product is Oncology Intelligence™ — highly predictive therapeutic response data derived from advanced models of cancer. We partner with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials.

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img